{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T13:09:37Z","timestamp":1792760977449,"version":"4.5.0"},"reference-count":279,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,7,29]],"date-time":"2025-07-29T00:00:00Z","timestamp":1753747200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biomedicine &amp; Pharmacotherapy"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1016\/j.biopha.2025.118392","type":"journal-article","created":{"date-parts":[[2025,8,5]],"date-time":"2025-08-05T13:25:30Z","timestamp":1754400330000},"page":"118392","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"special_numbering":"C","title":["Pharmacogenomics in cardiac therapy: Personalizing treatment for heart health"],"prefix":"10.1016","volume":"190","author":[{"given":"Niloofar","family":"Naderi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amir Ghaffari","family":"Jolfayi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amir","family":"Azimi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Majid","family":"Maleki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3499-044X","authenticated-orcid":false,"given":"Samira","family":"Kalayinia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.biopha.2025.118392_bib1","series-title":"MicroRNA in Regenerative Medicine","first-page":"991","article-title":"Drug\u2013MicroRNA Cross-Talk","author":"Monroig","year":"2015"},{"key":"10.1016\/j.biopha.2025.118392_bib2","series-title":"Bioinformatics","first-page":"305","article-title":"Pharmacokinetics and pharmacodynamics analysis of drug candidates","author":"Singh","year":"2022"},{"key":"10.1016\/j.biopha.2025.118392_bib3","series-title":"Pharmacogenetics","article-title":"Pharmacogenomics of \u201cCore\u201d essential medicines","author":"Sello","year":"2021"},{"issue":"4","key":"10.1016\/j.biopha.2025.118392_bib4","first-page":"191","article-title":"Pharmacogenomics: the right drug to the right person","volume":"1","author":"Aneesh","year":"2009","journal-title":"J. Clin. Med. Res."},{"key":"10.1016\/j.biopha.2025.118392_bib5","series-title":"Clinical Applications for Next-Generation Sequencing","first-page":"217","article-title":"Next generation sequencing in pharmacogenomics","author":"Demkow","year":"2016"},{"issue":"12","key":"10.1016\/j.biopha.2025.118392_bib6","doi-asserted-by":"crossref","DOI":"10.1111\/jcmm.18461","article-title":"Copy number variations: the potential association genetic cause in severe cardiovascular diseases with unknown aetiology","volume":"28","author":"Naderi","year":"2024","journal-title":"J. Cell. Mol. Med."},{"issue":"3","key":"10.1016\/j.biopha.2025.118392_bib7","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/S0169-5002(02)00224-6","article-title":"DNA repair and cisplatin resistance in non-small-cell lung cancer","volume":"38","author":"Rosell","year":"2002","journal-title":"Lung Cancer"},{"issue":"5","key":"10.1016\/j.biopha.2025.118392_bib8","doi-asserted-by":"crossref","DOI":"10.1097\/MS9.0000000000001744","article-title":"Unlocking the gut-heart axis: exploring the role of gut microbiota in cardiovascular health and disease","volume":"86","author":"Shariff","year":"2024","journal-title":"Ann. Med. Surg."},{"issue":"12","key":"10.1016\/j.biopha.2025.118392_bib9","doi-asserted-by":"crossref","DOI":"10.1002\/hsr2.1773","article-title":"Unveiling the sleep-cardiovascular connection: novel perspectives and interventions\u2014a narrative review","volume":"6","author":"Berjaoui","year":"2023","journal-title":"Health Sci. Rep."},{"issue":"7","key":"10.1016\/j.biopha.2025.118392_bib10","doi-asserted-by":"crossref","DOI":"10.1002\/cpz1.189","article-title":"Pharmacogenomics in cardiovascular diseases","volume":"1","author":"McDonough","year":"2021","journal-title":"Curr. Protoc."},{"issue":"3","key":"10.1016\/j.biopha.2025.118392_bib11","doi-asserted-by":"crossref","first-page":"147","DOI":"10.3325\/cmj.2020.61.147","article-title":"Use of pharmacogenomics in elderly patients treated for cardiovascular diseases","volume":"61","author":"Bo\u017eina","year":"2020","journal-title":"Croat. Med. J."},{"key":"10.1016\/j.biopha.2025.118392_bib12","unstructured":"2015, A.L.KaufmanJ.SpitzM.JacobsM.SorrentinoS.YuenK.Danahey, Evidence for clinical implementation of pharmacogenomics in cardiac drugs Elsevier Mayo Clinic Proceedings,A.L.KaufmanJ.SpitzM.JacobsM.SorrentinoS.YuenK.Danahey."},{"issue":"1","key":"10.1016\/j.biopha.2025.118392_bib13","first-page":"75","article-title":"Human genetics: problems and approaches","volume":"69","author":"Vogel","year":"1997","journal-title":"Genet. Res."},{"issue":"2","key":"10.1016\/j.biopha.2025.118392_bib14","article-title":"A brief history from the\" abstain from beans\" of pythagoras to the present","volume":"29","author":"Meletis","year":"2012","journal-title":"Arch. Hell. Med. \/Arheia Ellenikes Iatr."},{"issue":"3","key":"10.1016\/j.biopha.2025.118392_bib15","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1111\/j.1399-0004.2005.00487.x","article-title":"Sir archibald garrod and Alkaptonuria\u2013\u2018story of metabolic genetics","volume":"68","author":"Prasad","year":"2005","journal-title":"Clin. Genet."},{"key":"10.1016\/j.biopha.2025.118392_bib16","unstructured":"Moderne probleme der humangenetik Springer Ergebnisse der inneren medizin und kinderheilkunde F.Vogel, 1959."},{"issue":"7","key":"10.1016\/j.biopha.2025.118392_bib17","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1001\/jama.1957.72980250010016","article-title":"Drug reactions, enzymes, and biochemical genetics","volume":"165","author":"Motulsky","year":"1957","journal-title":"J. Am. Med. Assoc."},{"issue":"5197","key":"10.1016\/j.biopha.2025.118392_bib18","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1136\/bmj.2.5197.485","article-title":"Genetic control of isoniazid metabolism in man","volume":"2","author":"Evans","year":"1960","journal-title":"Br. Med. J."},{"key":"10.1016\/j.biopha.2025.118392_bib19","volume":"12","author":"Kalow","year":"1962"},{"issue":"8038","key":"10.1016\/j.biopha.2025.118392_bib20","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1016\/S0140-6736(77)91430-1","article-title":"Polymorphic hydroxylation of debrisoquine in man","volume":"310","author":"Mahgoub","year":"1977","journal-title":"Lancet"},{"key":"10.1016\/j.biopha.2025.118392_bib21","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1007\/BF00562059","article-title":"Defective N-oxidation of sparteine in man: a new pharmacogenetic defect","volume":"16","author":"Eichelbaum","year":"1979","journal-title":"Eur. J. Clin. Pharmacol."},{"issue":"6155","key":"10.1016\/j.biopha.2025.118392_bib22","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1038\/331442a0","article-title":"Characterization of the common genetic defect in humans deficient in debrisoquine metabolism","volume":"331","author":"Gonzalez","year":"1988","journal-title":"Nature"},{"issue":"04","key":"10.1016\/j.biopha.2025.118392_bib23","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1055\/a-0979-2322","article-title":"From the origins of pharmacogenetics to first applications in psychiatry","volume":"53","author":"M\u00fcller","year":"2020","journal-title":"Pharmacopsychiatry"},{"key":"10.1016\/j.biopha.2025.118392_bib24","doi-asserted-by":"crossref","DOI":"10.1177\/2045125319896650","article-title":"Landmarks of pharmacogenomics and some considerations for clinical practice","volume":"9","author":"Ampong","year":"2019","journal-title":"Ther. Adv. Psychopharmacol."},{"issue":"2","key":"10.1016\/j.biopha.2025.118392_bib25","article-title":"From pharmacogenetics to pharmaco-omics: milestones and future directions","volume":"3","author":"Auwerx","year":"2022","journal-title":"Hum. Genet. Genom. Adv."},{"issue":"5","key":"10.1016\/j.biopha.2025.118392_bib26","doi-asserted-by":"crossref","first-page":"481","DOI":"10.7861\/clinmedicine.16-5-481","article-title":"Adverse drug reactions","volume":"16","author":"Coleman","year":"2016","journal-title":"Clin. Med."},{"issue":"2","key":"10.1016\/j.biopha.2025.118392_bib27","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/S0002-9343(00)00451-4","article-title":"Incidence and preventability of adverse drug events in nursing homes","volume":"109","author":"Gurwitz","year":"2000","journal-title":"Am. J. Med."},{"issue":"5","key":"10.1016\/j.biopha.2025.118392_bib28","doi-asserted-by":"crossref","first-page":"487","DOI":"10.3390\/ph14050487","article-title":"The influence of pharmacogenetics on the clinical relevance of pharmacokinetic drug\u2013drug interactions: drug\u2013gene, drug\u2013gene\u2013gene and drug\u2013drug\u2013gene interactions","volume":"14","author":"Hahn","year":"2021","journal-title":"Pharmaceuticals"},{"issue":"11","key":"10.1016\/j.biopha.2025.118392_bib29","article-title":"Predicting drug-drug and drug-gene interactions in a community pharmacy population","volume":"28","author":"Dowd","year":"2022","journal-title":"Am. J. Manag. Care"},{"issue":"2","key":"10.1016\/j.biopha.2025.118392_bib30","doi-asserted-by":"crossref","DOI":"10.53388\/DCT2022006","article-title":"Complex diseases demand novel treatment strategies: understanding drug combination","volume":"4","author":"Siqueira de","year":"2022","journal-title":"Drug Comb. Ther."},{"key":"10.1016\/j.biopha.2025.118392_bib31","first-page":"879","article-title":"Drug\u2013drug\u2013gene interactions in cardiovascular medicine","author":"Asiimwe","year":"2022","journal-title":"Pharm. Pers. Med."},{"issue":"6","key":"10.1016\/j.biopha.2025.118392_bib32","doi-asserted-by":"crossref","first-page":"1718","DOI":"10.1002\/cpt.3604","article-title":"A comprehensive CYP2D6 drug\u2013drug\u2013gene interaction network for application in precision dosing and drug development","volume":"117","author":"R\u00fcdesheim","year":"2025","journal-title":"Clin. Pharmacol. Ther."},{"issue":"6","key":"10.1016\/j.biopha.2025.118392_bib33","doi-asserted-by":"crossref","first-page":"1718","DOI":"10.1002\/cpt.3604","article-title":"A comprehensive CYP2D6 drug-drug-gene interaction network for application in precision dosing and drug development","volume":"117","author":"R\u00fcdesheim","year":"2025","journal-title":"Clin. Pharm. Ther."},{"issue":"2","key":"10.1016\/j.biopha.2025.118392_bib34","doi-asserted-by":"crossref","first-page":"135","DOI":"10.4103\/0250-474X.156543","article-title":"Pharmacogenetics, pharmacogenomics and ayurgenomics for personalized Medicine: a paradigm shift","volume":"77","author":"Gupta","year":"2015","journal-title":"Indian J. Pharm. Sci."},{"issue":"4","key":"10.1016\/j.biopha.2025.118392_bib35","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1046\/j.0306-5251.2001.01498.x","article-title":"Pharmacogenetics and pharmacogenomics","volume":"52","author":"Pirmohamed","year":"2001","journal-title":"Br. J. Clin. Pharmacol."},{"issue":"6","key":"10.1016\/j.biopha.2025.118392_bib36","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1002\/cpt.258","article-title":"Heritability of metoprolol and torsemide pharmacokinetics","volume":"98","author":"Matthaei","year":"2015","journal-title":"Clin. Pharmacol. Ther."},{"issue":"6","key":"10.1016\/j.biopha.2025.118392_bib37","doi-asserted-by":"crossref","first-page":"364","DOI":"10.7196\/SAMJ.2019.v109i6.14069","article-title":"An overview of the genetic basis of cardiovascular disease","volume":"109","author":"Laing","year":"2019","journal-title":"South Afr. Med. J."},{"issue":"3","key":"10.1016\/j.biopha.2025.118392_bib38","doi-asserted-by":"crossref","first-page":"107","DOI":"10.5530\/jcdr.2015.3.1","article-title":"Current molecular diagnostics of cardiovascular diseases-a step closer to personalized medicine","volume":"6","author":"Abhik","year":"2015","journal-title":"J. Cardiovasc. Dis. Res."},{"issue":"4","key":"10.1016\/j.biopha.2025.118392_bib39","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1001\/jamacardio.2019.5954","article-title":"Association of monogenic vs polygenic hypercholesterolemia with risk of atherosclerotic cardiovascular disease","volume":"5","author":"Trinder","year":"2020","journal-title":"JAMA Cardiol."},{"issue":"3","key":"10.1016\/j.biopha.2025.118392_bib40","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1097\/HCO.0b013e32835220e3","article-title":"Genetic determinants of response to cardiovascular drugs","volume":"27","author":"Wells","year":"2012","journal-title":"Curr. Opin. Cardiol."},{"issue":"9","key":"10.1016\/j.biopha.2025.118392_bib41","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1161\/CIRCRESAHA.117.310965","article-title":"Opportunities and challenges in cardiovascular pharmacogenomics: from discovery to implementation","volume":"122","author":"Roden","year":"2018","journal-title":"Circ. Res."},{"issue":"3","key":"10.1016\/j.biopha.2025.118392_bib42","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1016\/j.cll.2016.05.006","article-title":"Fundamentals of pharmacogenetics in personalized, precision Medicine","volume":"36","author":"Valdes","year":"2016","journal-title":"Clin. Lab. Med."},{"key":"10.1016\/j.biopha.2025.118392_bib43","doi-asserted-by":"crossref","DOI":"10.1016\/S0272-2712(16)30047-6","article-title":"Pharmacogenomics and precision medicine, an issue of","author":"Reynolds","year":"2016","journal-title":"Clin. Lab. Med. Elsevier Health Sci."},{"issue":"1","key":"10.1016\/j.biopha.2025.118392_bib44","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1093\/ehjcvp\/pvab018","article-title":"The role of pharmacogenomics in contemporary cardiovascular therapy: a position statement from the european society of cardiology working group on cardiovascular pharmacotherapy","volume":"8","author":"Magavern","year":"2022","journal-title":"Eur. Heart J. Cardiovasc. Pharmacother."},{"issue":"1","key":"10.1016\/j.biopha.2025.118392_bib45","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1177\/1074248415590196","article-title":"Cardiovascular pharmacokinetics, pharmacodynamics, and pharmacogenomics for the clinical practitioner","volume":"21","author":"Sleder","year":"2016","journal-title":"J. Cardiovasc. Pharmacol. Ther."},{"key":"10.1016\/j.biopha.2025.118392_bib46","series-title":"Nursing Pharmacology","article-title":"Pharmacokinetics & pharmacodynamics","author":"for Nursing","year":"2023"},{"key":"10.1016\/j.biopha.2025.118392_bib47","series-title":"Critical Care Nephrology","first-page":"600","article-title":"Poisoning: kinetics to therapeutics","author":"Lu","year":"2019"},{"issue":"5","key":"10.1016\/j.biopha.2025.118392_bib48","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1515\/cclm-2019-0820","article-title":"Hyphenated mass spectrometry techniques for assessing medication adherence: advantages, challenges, clinical applications and future perspectives","volume":"58","author":"Tanna","year":"2020","journal-title":"Clin. Chem. Lab. Med. (CCLM)"},{"key":"10.1016\/j.biopha.2025.118392_bib49","series-title":"Volume of Distribution","author":"Mansoor","year":"2023"},{"key":"10.1016\/j.biopha.2025.118392_bib50","doi-asserted-by":"crossref","first-page":"S23","DOI":"10.1002\/jcph.671","article-title":"Importance of hepatic transporters in clinical disposition of drugs and their metabolites","volume":"56","author":"Patel","year":"2016","journal-title":"J. Clin. Pharmacol."},{"issue":"1","key":"10.1016\/j.biopha.2025.118392_bib51","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.cld.2016.08.001","article-title":"Drug metabolism in the liver","volume":"21","author":"Almazroo","year":"2017","journal-title":"Clin. Liver Dis."},{"key":"10.1016\/j.biopha.2025.118392_bib52","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2022.115006","article-title":"The mechanisms of interactions of psychotropic drugs with liver and brain cytochrome P450 and their significance for drug effect and drug-drug interactions","volume":"199","author":"Daniel","year":"2022","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.biopha.2025.118392_bib53","doi-asserted-by":"crossref","DOI":"10.1016\/j.mpaic.2023.05.011","article-title":"Modes of drug elimination and bioactive metabolites","author":"Chillistone","year":"2023","journal-title":"Anaesth. Intensive Care Med."},{"key":"10.1016\/j.biopha.2025.118392_bib54","author":"Allegaert","year":"2023","journal-title":"Neonatal Pharmacol."},{"key":"10.1016\/j.biopha.2025.118392_bib55","doi-asserted-by":"crossref","unstructured":"Roberts S. Drug Metabolism| Overview, 2005.","DOI":"10.1016\/B0-12-369397-7\/00108-4"},{"issue":"9","key":"10.1016\/j.biopha.2025.118392_bib56","first-page":"630","article-title":"Drug\u2013gene interactions: inherent variability in drug maintenance dose requirements","volume":"39","author":"Westervelt","year":"2014","journal-title":"Pharm. Ther."},{"issue":"3","key":"10.1016\/j.biopha.2025.118392_bib57","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1016\/j.ccc.2021.03.001","article-title":"Pharmacokinetic and pharmacodynamic principles for toxicology","volume":"37","author":"Lista","year":"2021","journal-title":"Crit. Care Clin."},{"issue":"2","key":"10.1016\/j.biopha.2025.118392_bib58","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1586\/ers.12.9","article-title":"Genetic basis for personalized medicine in asthma","volume":"6","author":"Portelli","year":"2012","journal-title":"Expert Rev. Respir. Med."},{"issue":"3","key":"10.1016\/j.biopha.2025.118392_bib59","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1111\/j.1365-2222.2011.03696.x","article-title":"Pharmacogenetics of \u03b22 adrenergic receptor gene polymorphisms, long-acting \u03b2-agonists and asthma","volume":"41","author":"Chung","year":"2011","journal-title":"Clin. Exp. Allergy"},{"issue":"10","key":"10.1016\/j.biopha.2025.118392_bib60","first-page":"7","article-title":"Genetics and pharmacogenetics in the diagnosis and therapy of cardiovascular diseases","volume":"90","author":"Krasi","year":"2019","journal-title":"Acta Bio Med. Atenei Parm."},{"issue":"3","key":"10.1016\/j.biopha.2025.118392_bib61","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1038\/clpt.2010.279","article-title":"CPIC: clinical pharmacogenetics implementation consortium of the pharmacogenomics research network","volume":"89","author":"Relling","year":"2011","journal-title":"Clin. Pharmacol. Ther."},{"issue":"1","key":"10.1016\/j.biopha.2025.118392_bib62","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1146\/annurev-pharmtox-010814-124835","article-title":"Preemptive clinical pharmacogenetics implementation: current programs in five US medical centers","volume":"55","author":"Dunnenberger","year":"2015","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"issue":"8","key":"10.1016\/j.biopha.2025.118392_bib63","doi-asserted-by":"crossref","DOI":"10.1002\/cpz1.226","article-title":"PharmGKB, an integrated resource of pharmacogenomic knowledge","volume":"1","author":"Gong","year":"2021","journal-title":"Curr. Protoc."},{"key":"10.1016\/j.biopha.2025.118392_bib64","doi-asserted-by":"crossref","DOI":"10.21037\/jlpm-2019-cpm-05","article-title":"Pharmacogenomics in cardiovascular precision medicine","volume":"5","author":"Zhou","year":"2020","journal-title":"J. Lab. Precis. Med."},{"key":"10.1016\/j.biopha.2025.118392_bib65","series-title":"Genetic Diversity and Disease Susceptibility","article-title":"Polymorphisms","author":"Sukhumsirichart","year":"2018"},{"issue":"21","key":"10.1016\/j.biopha.2025.118392_bib66","doi-asserted-by":"crossref","first-page":"2101","DOI":"10.2146\/ajhp060068","article-title":"Common laboratory methods in pharmacogenomics studies","volume":"63","author":"Aquilante","year":"2006","journal-title":"Am. J. HealthSyst. Pharm."},{"issue":"12","key":"10.1016\/j.biopha.2025.118392_bib67","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.3390\/genes11121456","article-title":"Technologies for pharmacogenomics: a review","volume":"11","author":"van der Lee","year":"2020","journal-title":"Genes"},{"key":"10.1016\/j.biopha.2025.118392_bib68","doi-asserted-by":"crossref","DOI":"10.3389\/fgene.2019.00426","article-title":"Long-read sequencing emerging in medical genetics","volume":"10","author":"Mantere","year":"2019","journal-title":"Front. Genet."},{"issue":"1","key":"10.1016\/j.biopha.2025.118392_bib69","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.tibtech.2018.07.013","article-title":"Single-molecule sequencing: towards clinical applications","volume":"37","author":"Ameur","year":"2019","journal-title":"Trends Biotechnol."},{"issue":"2","key":"10.1016\/j.biopha.2025.118392_bib70","doi-asserted-by":"crossref","first-page":"119","DOI":"10.2217\/pme.15.57","article-title":"Physicians\u2019 attitudes toward pharmacogenetic testing before and after pharmacogenetic education","volume":"13","author":"Luzum","year":"2016","journal-title":"Pers. Med."},{"issue":"1","key":"10.1016\/j.biopha.2025.118392_bib71","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1002\/cpt.1651","article-title":"The clinical pharmacogenetics implementation consortium: 10 years later","volume":"107","author":"Relling","year":"2020","journal-title":"Clin. Pharmacol. Ther."},{"issue":"23","key":"10.1016\/j.biopha.2025.118392_bib72","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1016\/j.jacc.2014.03.018","article-title":"Anti-PCSK9 monotherapy for hypercholesterolemia: the MENDEL-2 randomized, controlled phase III clinical trial of evolocumab","volume":"63","author":"Koren","year":"2014","journal-title":"J. Am. Coll. Cardiol."},{"issue":"9","key":"10.1016\/j.biopha.2025.118392_bib73","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1038\/s41569-021-00549-w","article-title":"Pharmacogenetics to guide cardiovascular drug therapy","volume":"18","author":"Duarte","year":"2021","journal-title":"Nat. Rev. Cardiol."},{"issue":"3","key":"10.1016\/j.biopha.2025.118392_bib74","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1038\/s41436-020-00995-w","article-title":"A model-based cost-effectiveness analysis of pharmacogenomic panel testing in cardiovascular disease management: preemptive, reactive, or none?","volume":"23","author":"Zhu","year":"2021","journal-title":"Genet. Med."},{"key":"10.1016\/j.biopha.2025.118392_bib75","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1007\/978-3-030-62080-6_13","article-title":"Personalized therapy of cardiovascular disorders","author":"Jain","year":"2021","journal-title":"Textb. Pers. Med."},{"issue":"4","key":"10.1016\/j.biopha.2025.118392_bib76","doi-asserted-by":"crossref","DOI":"10.1002\/hsr2.70727","article-title":"Addressing cardiometabolic challenges in HIV: insights, impact, and best practices for optimal management\u2014a narrative review","volume":"8","author":"Mugisha","year":"2025","journal-title":"Health Sci. Rep."},{"issue":"6","key":"10.1016\/j.biopha.2025.118392_bib77","doi-asserted-by":"crossref","first-page":"595","DOI":"10.2217\/pme-2021-0087","article-title":"Omics technologies in personalized combination therapy for cardiovascular diseases: challenges and opportunities","volume":"18","author":"Banerjee","year":"2021","journal-title":"Pers. Med."},{"key":"10.1016\/j.biopha.2025.118392_bib78","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1007\/978-1-4939-2553-7_14","article-title":"Personalized management of cardiovascular disorders","author":"Jain","year":"2015","journal-title":"Textb. Pers. Med."},{"issue":"5","key":"10.1016\/j.biopha.2025.118392_bib79","doi-asserted-by":"crossref","first-page":"511","DOI":"10.2217\/14622416.9.5.511","article-title":"Influence of CYP2C9 and VKORC1 on warfarin dose, anticoagulation attainment and maintenance among European-Americans and African-Americans","volume":"9","author":"Limdi","year":"2008","journal-title":"Pharmacogenomics"},{"key":"10.1016\/j.biopha.2025.118392_bib80","series-title":"Medical Genetics Summaries. Bethesda (MD): National Center for Biotechnology Information (US)","article-title":"Clopidogrel therapy and CYP2C19 genotype","author":"Dean","year":"2012"},{"issue":"3","key":"10.1016\/j.biopha.2025.118392_bib81","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/j.thromres.2014.12.007","article-title":"Effect of high-dose clopidogrel according to CYP2C19*2 genotype in patients undergoing percutaneous coronary intervention- a systematic review and meta-analysis","volume":"135","author":"Zhang","year":"2015","journal-title":"Thromb. Res."},{"issue":"8","key":"10.1016\/j.biopha.2025.118392_bib82","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1056\/NEJMoa0801936","article-title":"SLCO1B1 variants and statin-induced myopathy--a genomewide study","volume":"359","author":"Link","year":"2008","journal-title":"N. Engl. J. Med."},{"issue":"6","key":"10.1016\/j.biopha.2025.118392_bib83","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1038\/clpt.2013.161","article-title":"SLCO1B1 genetic variant associated with statin-induced myopathy: a proof-of-concept study using the clinical practice research datalink","volume":"94","author":"Carr","year":"2013","journal-title":"Clin. Pharmacol. Ther."},{"issue":"9","key":"10.1016\/j.biopha.2025.118392_bib84","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.2337\/diabetes.47.9.1507","article-title":"Effect of angiotensin-converting enzyme (ACE) gene polymorphism on progression of renal disease and the influence of ACE inhibition in IDDM patients: findings from the EUCLID randomized controlled trial. Eurodiab controlled trial of lisinopril in IDDM","volume":"47","author":"Penno","year":"1998","journal-title":"Diabetes"},{"issue":"9","key":"10.1016\/j.biopha.2025.118392_bib85","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1111\/j.1440-1681.2012.05736.x","article-title":"Effect of the Arg389Gly \u03b2\u2081-adrenoceptor polymorphism on plasma renin activity and heart rate, and the genotype-dependent response to metoprolol treatment","volume":"39","author":"Petersen","year":"2012","journal-title":"Clin. Exp. Pharmacol. Physiol."},{"issue":"25","key":"10.1016\/j.biopha.2025.118392_bib86","doi-asserted-by":"crossref","first-page":"2982","DOI":"10.1016\/j.jacc.2020.11.010","article-title":"Global burden of cardiovascular diseases and risk factors, 1990\u20132019: update from the GBD 2019 study","volume":"76","author":"Giovanni","year":"2020","journal-title":"J. Am. Coll. Cardiol."},{"issue":"5","key":"10.1016\/j.biopha.2025.118392_bib87","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1111\/joim.13772","article-title":"Precision medicine in cardiovascular therapeutics: evaluating the role of pharmacogenetic analysis prior to drug treatment","volume":"295","author":"Ingelman-Sundberg","year":"2024","journal-title":"J. Intern. Med."},{"issue":"2","key":"10.1016\/j.biopha.2025.118392_bib88","doi-asserted-by":"crossref","first-page":"91","DOI":"10.3949\/ccjm.87a.19073","article-title":"Pharmacogenomics: an evolving clinical tool for precision medicine","volume":"87","author":"Moc","year":"2020","journal-title":"Clevel. Clin. J. Med."},{"issue":"20","key":"10.1016\/j.biopha.2025.118392_bib89","doi-asserted-by":"crossref","first-page":"3214","DOI":"10.3390\/cells11203214","article-title":"Anticoagulants: a short history, their mechanism of action, pharmacology, and indications","volume":"11","author":"Heestermans","year":"2022","journal-title":"Cells"},{"issue":"1","key":"10.1016\/j.biopha.2025.118392_bib90","doi-asserted-by":"crossref","first-page":"11","DOI":"10.5811\/westjem.2014.12.22933","article-title":"Anticoagulation drug therapy: a review","volume":"16","author":"Harter","year":"2015","journal-title":"West. J. Emerg. Med."},{"issue":"4","key":"10.1016\/j.biopha.2025.118392_bib91","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1080\/17425255.2023.2220961","article-title":"Lessons learned from the influence of CYP2C9 genotype on warfarin dosing","volume":"19","author":"Tidbury","year":"2023","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"issue":"7","key":"10.1016\/j.biopha.2025.118392_bib92","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1016\/j.clinthera.2023.04.006","article-title":"Efficacy of warfarin therapy guided by pharmacogenetics: a real-world investigation among han Taiwanese","volume":"45","author":"Liu","year":"2023","journal-title":"Clin. Ther."},{"issue":"15","key":"10.1016\/j.biopha.2025.118392_bib93","doi-asserted-by":"crossref","first-page":"1714","DOI":"10.1161\/CIRCULATIONAHA.106.661751","article-title":"Genetics of cardiovascular diseases: from single mutations to the whole genome","volume":"116","author":"Cambien","year":"2007","journal-title":"Circulation"},{"issue":"2","key":"10.1016\/j.biopha.2025.118392_bib94","first-page":"7","article-title":"Being precise with anticoagulation to reduce adverse drug reactions: are we there yet?","volume":"24","author":"Cross","year":"2024","journal-title":"Pharm. J."},{"key":"10.1016\/j.biopha.2025.118392_bib95","first-page":"609","article-title":"One rare warfarin resistance case and possible mechanism exploration","author":"Zhao","year":"2023","journal-title":"Pharm. Pers. Med."},{"issue":"9894","key":"10.1016\/j.biopha.2025.118392_bib96","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1016\/S0140-6736(13)60681-9","article-title":"Genetic variants associated with warfarin dose in African-American individuals: a genome-wide association study","volume":"382","author":"Perera","year":"2013","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.biopha.2025.118392_bib97","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pgen.1000433","article-title":"A genome-wide association study confirms VKORC1, CYP2C9, and CYP4F2 as principal genetic determinants of warfarin dose","volume":"5","author":"Takeuchi","year":"2009","journal-title":"PLoS Genet."},{"issue":"4","key":"10.1016\/j.biopha.2025.118392_bib98","first-page":"784","article-title":"The largest prospective warfarin-treated cohort supports genetic forecasting","volume":"113","author":"Wadelius","year":"2009","journal-title":"Blood J. Am. Soc. Hematol."},{"issue":"10","key":"10.1016\/j.biopha.2025.118392_bib99","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.0020312","article-title":"A C1173T dimorphism in the VKORC1 gene determines coumarin sensitivity and bleeding risk","volume":"2","author":"Reitsma","year":"2005","journal-title":"PLoS Med."},{"issue":"10","key":"10.1016\/j.biopha.2025.118392_bib100","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1056\/NEJMoa0708078","article-title":"Genetic determinants of response to warfarin during initial anticoagulation","volume":"358","author":"Schwarz","year":"2008","journal-title":"N. Engl. J. Med."},{"issue":"6","key":"10.1016\/j.biopha.2025.118392_bib101","doi-asserted-by":"crossref","first-page":"2477","DOI":"10.1182\/blood-2006-08-038984","article-title":"A coding VKORC1 Asp36Tyr polymorphism predisposes to warfarin resistance","volume":"109","author":"Loebstein","year":"2007","journal-title":"Blood"},{"issue":"22","key":"10.1016\/j.biopha.2025.118392_bib102","doi-asserted-by":"crossref","first-page":"2285","DOI":"10.1056\/NEJMoa044503","article-title":"Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose","volume":"352","author":"Rieder","year":"2005","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.biopha.2025.118392_bib103","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1007\/s00439-006-0260-8","article-title":"Association of warfarin dose with genes involved in its action and metabolism","volume":"121","author":"Wadelius","year":"2007","journal-title":"Hum. Genet."},{"issue":"2","key":"10.1016\/j.biopha.2025.118392_bib104","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1038\/sj.clpt.6100290","article-title":"Influence of CYP2C9 and VKORC1 1173C\/T genotype on the risk of hemorrhagic complications in African-American and European-American patients on warfarin","volume":"83","author":"Limdi","year":"2008","journal-title":"Clin. Pharmacol. Ther."},{"issue":"3","key":"10.1016\/j.biopha.2025.118392_bib105","first-page":"251","article-title":"Cytochrome P450 2C9 polymorphisms: a comprehensive review of the in-vitro and human data","volume":"12","author":"Lee","year":"2002","journal-title":"Pharm. Genom."},{"issue":"4","key":"10.1016\/j.biopha.2025.118392_bib106","doi-asserted-by":"crossref","first-page":"407","DOI":"10.2217\/pgs.11.164","article-title":"Predicting warfarin dosage in European\u2013Americans and African\u2013Americans using DNA samples linked to an electronic health record","volume":"13","author":"Ramirez","year":"2012","journal-title":"Pharmacogenomics"},{"issue":"6","key":"10.1016\/j.biopha.2025.118392_bib107","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1002\/cpt.1323","article-title":"Effect of CYP 4F2, VKORC 1, and CYP 2C9 in influencing coumarin dose: a single-patient data meta-analysis in more than 15,000 individuals","volume":"105","author":"Danese","year":"2019","journal-title":"Clin. Pharmacol. Ther."},{"issue":"8","key":"10.1016\/j.biopha.2025.118392_bib108","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1080\/17425255.2016.1194395","article-title":"The toxicology of heparin reversal with protamine: past, present and future","volume":"12","author":"Sokolowska","year":"2016","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"issue":"9","key":"10.1016\/j.biopha.2025.118392_bib109","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1002\/phar.1983","article-title":"Influence of human leukocyte antigen (HLA) alleles and killer cell immunoglobulin-like receptors (KIR) types on heparin-induced thrombocytopenia (HIT)","volume":"37","author":"Karnes","year":"2017","journal-title":"Pharmacother. J. Hum. Pharmacol. Drug Ther."},{"issue":"15","key":"10.1016\/j.biopha.2025.118392_bib110","first-page":"2397","article-title":"Increased risk of thrombosis in Fc\u03b3RIIA 131RR patients with HIT due to defective control of platelet activation by plasma IgG2","volume":"125","author":"Rollin","year":"2015","journal-title":"Blood J. Am. Soc. Hematol."},{"issue":"2","key":"10.1016\/j.biopha.2025.118392_bib111","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1309\/BMW4M8NQBV0TKFRX","article-title":"Platelet PlA2 polymorphism and the risk for thrombosis in heparin-induced thrombocytopenia","volume":"129","author":"Harris","year":"2008","journal-title":"Am. J. Clin. Pathol."},{"key":"10.1016\/j.biopha.2025.118392_bib112","doi-asserted-by":"crossref","first-page":"S104","DOI":"10.1016\/j.thromres.2012.08.013","article-title":"C0343 polymorphisms of protein tyrosine phosphatase CD148 influence Fcgammariia-dependent platelet activation and the risk of heparin-induced thrombocytopenia","volume":"130","author":"Rollin","year":"2012","journal-title":"Thromb. Res."},{"issue":"4","key":"10.1016\/j.biopha.2025.118392_bib113","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1016\/j.thromres.2011.09.033","article-title":"Interleukin-10 promoter microsatellite polymorphisms influence the immune response to heparin and the risk of heparin-induced thrombocytopenia","volume":"129","author":"Pouplard","year":"2012","journal-title":"Thromb. Res."},{"issue":"18","key":"10.1016\/j.biopha.2025.118392_bib114","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.2217\/pgs-2018-0147","article-title":"Pharmacogenetics to prevent heparin-induced thrombocytopenia: what do we know?","volume":"19","author":"Karnes","year":"2018","journal-title":"Pharmacogenomics"},{"key":"10.1016\/j.biopha.2025.118392_bib115","doi-asserted-by":"crossref","unstructured":"Nemer G., Hendi N.N. Pharmacogenomics of Cardiovascular Diseases: The Path to Precision Therapy, 2023.","DOI":"10.5772\/intechopen.113236"},{"issue":"1","key":"10.1016\/j.biopha.2025.118392_bib116","doi-asserted-by":"crossref","first-page":"37","DOI":"10.3390\/jpm11010037","article-title":"Pharmacogenetics of direct oral anticoagulants: a systematic review","volume":"11","author":"Raymond","year":"2021","journal-title":"J. Pers. Med."},{"issue":"1","key":"10.1016\/j.biopha.2025.118392_bib117","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3390\/jpm9010007","article-title":"Pharmacogenomics of novel direct oral anticoagulants: newly identified genes and genetic variants","volume":"9","author":"Kanuri","year":"2019","journal-title":"J. Pers. Med."},{"key":"10.1016\/j.biopha.2025.118392_bib118","first-page":"127","article-title":"The impact of ABCB1 (rs1045642 and rs4148738) and CES1 (rs2244613) gene polymorphisms on dabigatran equilibrium peak concentration in patients after total knee arthroplasty","author":"Sychev","year":"2018","journal-title":"Pharm. Pers. Med."},{"issue":"2","key":"10.1016\/j.biopha.2025.118392_bib119","doi-asserted-by":"crossref","first-page":"a003731","DOI":"10.1101\/mcs.a003731","article-title":"Pharmacogenomic considerations for antiplatelet agents: the era of precision medicine in stroke prevention and neurointerventional practice","volume":"5","author":"Bonney","year":"2019","journal-title":"Mol. Case Stud."},{"key":"10.1016\/j.biopha.2025.118392_bib120","first-page":"395","article-title":"Inhibition of prostaglandin biosynthesis as the mechanism of action of aspirin-like drugs","volume":"9","author":"Vane","year":"2014","journal-title":"Adv. Biosci."},{"issue":"6","key":"10.1016\/j.biopha.2025.118392_bib121","doi-asserted-by":"crossref","first-page":"577","DOI":"10.2217\/14622416.8.6.577","article-title":"Frequency of genetic polymorphisms of COX1, GPIIIa and P2Y1 in a Chinese population and association with attenuated response to aspirin","volume":"8","author":"Li","year":"2007","journal-title":"Pharmacogenomics"},{"issue":"4","key":"10.1016\/j.biopha.2025.118392_bib122","doi-asserted-by":"crossref","DOI":"10.1002\/jcla.22331","article-title":"Association of GPI a and COX-2 gene polymorphism with aspirin resistance","volume":"32","author":"Wang","year":"2018","journal-title":"J. Clin. Lab. Anal."},{"issue":"7","key":"10.1016\/j.biopha.2025.118392_bib123","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1097\/FPC.0b013e3283385420","article-title":"Clopidogrel pathway","volume":"20","author":"Sangkuhl","year":"2010","journal-title":"Pharm. Genom."},{"issue":"2","key":"10.1016\/j.biopha.2025.118392_bib124","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1007\/s40262-014-0230-6","article-title":"Clinical pharmacokinetics and pharmacodynamics of clopidogrel","volume":"54","author":"Jiang","year":"2015","journal-title":"Clin. Pharmacokinet."},{"issue":"5","key":"10.1016\/j.biopha.2025.118392_bib125","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1002\/cpt.1911","article-title":"Genomewide association study of platelet reactivity and cardiovascular response in patients treated with clopidogrel: a study by the international clopidogrel pharmacogenomics consortium","volume":"108","author":"Verma","year":"2020","journal-title":"Clin. Pharmacol. Ther."},{"issue":"10","key":"10.1016\/j.biopha.2025.118392_bib126","doi-asserted-by":"crossref","first-page":"969","DOI":"10.2217\/pgs-2017-0070","article-title":"The impact of clinical and genetic factors on ticagrelor and clopidogrel antiplatelet therapy","volume":"18","author":"Tatarunas","year":"2017","journal-title":"Pharmacogenomics"},{"issue":"1","key":"10.1016\/j.biopha.2025.118392_bib127","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1146\/annurev-pharmtox-051921-092701","article-title":"Pharmacogenetics of antiplatelet therapy","volume":"63","author":"Castrichini","year":"2023","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"issue":"2","key":"10.1016\/j.biopha.2025.118392_bib128","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1517\/14656566.2013.757303","article-title":"Ticagrelor: the first novel reversible P2Y12 inhibitor","volume":"14","author":"Htun","year":"2013","journal-title":"Expert Opin. Pharmacother."},{"issue":"5","key":"10.1016\/j.biopha.2025.118392_bib129","first-page":"419","article-title":"Prasugrel versus ticagrelor in patients with CYP2C19 loss-of-function genotypes: results of a randomized pharmacodynamic study in a feasibility investigation of rapid genetic testing","volume":"5","author":"Franchi","year":"2020","journal-title":"Basic Transl. Sci."},{"issue":"7","key":"10.1016\/j.biopha.2025.118392_bib130","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1038\/s41431-023-01343-7","article-title":"Diagnosis and management of vascular Ehlers-Danlos syndrome: experience of the UK national diagnostic service, sheffield","volume":"31","author":"Bowen","year":"2023","journal-title":"Eur. J. Hum. Genet."},{"issue":"3","key":"10.1016\/j.biopha.2025.118392_bib131","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/0163-7258(90)90025-W","article-title":"The genetic polymorphism of debrisoquine\/sparteine metabolism\u2014clinical aspects","volume":"46","author":"Eichelbaum","year":"1990","journal-title":"Pharmacol. Ther."},{"issue":"6","key":"10.1016\/j.biopha.2025.118392_bib132","doi-asserted-by":"crossref","first-page":"806","DOI":"10.2174\/1381612820666141024151119","article-title":"Antihypertensive drugs metabolism: an update to pharmacokinetic profiles and computational approaches","volume":"21","author":"Zisaki","year":"2015","journal-title":"Curr. Pharm. Des."},{"issue":"10","key":"10.1016\/j.biopha.2025.118392_bib133","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1080\/17425255.2020.1803279","article-title":"Pharmacogenetic factors affecting \u03b2-blocker metabolism and response","volume":"16","author":"Thomas","year":"2020","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"issue":"4","key":"10.1016\/j.biopha.2025.118392_bib134","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1002\/cpt.3351","article-title":"Clinical pharmacogenetics implementation consortium guideline (CPIC) for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 genotypes and beta-blocker therapy","volume":"116","author":"Duarte","year":"2024","journal-title":"Clin. Pharmacol. Ther."},{"issue":"1","key":"10.1016\/j.biopha.2025.118392_bib135","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1111\/j.1476-5381.2009.00185.x","article-title":"cAMP signal transduction in the heart: understanding spatial control for the development of novel therapeutic strategies","volume":"158","author":"Zaccolo","year":"2009","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.biopha.2025.118392_bib136","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2021.112069","article-title":"Pharmacogenetic polymorphisms affecting bisoprolol response","volume":"142","author":"Casta\u00f1o-Amores","year":"2021","journal-title":"Biomed. Pharmacother."},{"issue":"6","key":"10.1016\/j.biopha.2025.118392_bib137","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1592\/phco.27.6.874","article-title":"Pharmacogenetics of \u03b2-Blockers","volume":"27","author":"Shin","year":"2007","journal-title":"Pharmacother. J. Hum. Pharmacol. Drug Ther."},{"issue":"1","key":"10.1016\/j.biopha.2025.118392_bib138","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1038\/clpt.2012.18","article-title":"Impact of the \u03b21-adrenoceptor Arg389Gly polymorphism on heart-rate responses to bisoprolol and carvedilol in heart-failure patients","volume":"92","author":"Rau","year":"2012","journal-title":"Clin. Pharmacol. Ther."},{"issue":"1","key":"10.1016\/j.biopha.2025.118392_bib139","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1038\/sj.bjp.0705753","article-title":"Markedly reduced effects of (\u2212)-isoprenaline but not of (\u2212)-CGP12177 and unchanged affinity of \u03b2-blockers at Gly389-\u03b21-adrenoceptors compared to Arg389-\u03b21-adrenoceptors","volume":"142","author":"Joseph","year":"2004","journal-title":"Br. J. Pharmacol."},{"issue":"14","key":"10.1016\/j.biopha.2025.118392_bib140","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1056\/NEJMoa010819","article-title":"The effect of common polymorphisms of the \u03b22-adrenergic receptor on agonist-mediated vascular desensitization","volume":"345","author":"Dishy","year":"2001","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.biopha.2025.118392_bib141","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1165\/ajrcmb.13.1.7598936","article-title":"Influence of beta 2-adrenergic receptor genotypes on signal transduction in human airway smooth muscle cells","volume":"13","author":"Green","year":"1995","journal-title":"Am. J. Respir. Cell Mol. Biol."},{"issue":"32","key":"10.1016\/j.biopha.2025.118392_bib142","doi-asserted-by":"crossref","first-page":"9414","DOI":"10.1021\/bi00198a006","article-title":"Amino-terminal polymorphisms of the human. Beta. 2-adrenergic receptor impart distinct agonist-promoted regulatory properties","volume":"33","author":"Green","year":"1994","journal-title":"Biochemistry"},{"issue":"1","key":"10.1016\/j.biopha.2025.118392_bib143","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.clpt.2006.03.004","article-title":"\u03b21-Adrenergic receptor polymorphisms influence the response to metoprolol monotherapy in patients with essential hypertension","volume":"80","author":"Liu","year":"2006","journal-title":"Clin. Pharmacol. Ther."},{"issue":"6758","key":"10.1016\/j.biopha.2025.118392_bib144","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1038\/46040","article-title":"Two functionally distinct \u03b12-adrenergic receptors regulate sympathetic neurotransmission","volume":"402","author":"Hein","year":"1999","journal-title":"Nature"},{"key":"10.1016\/j.biopha.2025.118392_bib145","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1471-2350-9-93","article-title":"Multiple interactions between the alpha 2C-and beta 1-adrenergic receptors influence heart failure survival","volume":"9","author":"Kardia","year":"2008","journal-title":"BMC Med. Genet."},{"issue":"3","key":"10.1016\/j.biopha.2025.118392_bib146","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1097\/01213011-200503000-00002","article-title":"Sympathoneural and adrenomedullary functional effects of \u03b12C-adrenoreceptor gene polymorphism in healthy humans","volume":"15","author":"Neumeister","year":"2005","journal-title":"Pharm. Genom."},{"issue":"9","key":"10.1016\/j.biopha.2025.118392_bib147","doi-asserted-by":"crossref","first-page":"6832","DOI":"10.1016\/S0021-9258(17)37451-3","article-title":"Identification, purification, and characterization of GRK5, a member of the family of g protein-coupled receptor kinases","volume":"269","author":"Premont","year":"1994","journal-title":"J. Biol. Chem."},{"issue":"5","key":"10.1016\/j.biopha.2025.118392_bib148","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1038\/nm1750","article-title":"A GRK5 polymorphism that inhibits \u03b2-adrenergic receptor signaling is protective in heart failure","volume":"14","author":"Liggett","year":"2008","journal-title":"Nat. Med."},{"issue":"5","key":"10.1016\/j.biopha.2025.118392_bib149","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1007\/s11883-016-0573-6","article-title":"Pharmacogenetics of lipid-lowering agents: precision or indecision medicine?","volume":"18","author":"Alfonsi","year":"2016","journal-title":"Curr. Atheroscler. Rep."},{"issue":"1","key":"10.1016\/j.biopha.2025.118392_bib150","doi-asserted-by":"crossref","first-page":"65","DOI":"10.2217\/pme-2022-0041","article-title":"Pharmacogenomics of lipid-lowering agents: the impact on efficacy and safety","volume":"20","author":"Shatnawi","year":"2023","journal-title":"Pers. Med."},{"issue":"9","key":"10.1016\/j.biopha.2025.118392_bib151","doi-asserted-by":"crossref","first-page":"877","DOI":"10.3390\/jpm11090877","article-title":"Pharmacogenomics variability of lipid-lowering therapies in familial hypercholesterolemia","volume":"11","author":"Hindi","year":"2021","journal-title":"J. Pers. Med."},{"issue":"6","key":"10.1016\/j.biopha.2025.118392_bib152","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1093\/eurheartj\/ehv563","article-title":"The impact of proprotein convertase subtilisin-kexin type 9 serine protease inhibitors on lipid levels and outcomes in patients with primary hypercholesterolaemia: a network meta-analysis","volume":"37","author":"Lipinski","year":"2016","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.biopha.2025.118392_bib153","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1161\/01.CIR.0000153341.46271.40","article-title":"The cholesterol ester transfer protein (CETP) taqIB variant, HDL cholesterol levels, cardiovascular risk and the efficacy of pravastatin treatment\u2013an individual patient meta-analisis of 13,677 subjects","volume":"17","author":"Boekholdt","year":"2005","journal-title":"Circulation"},{"issue":"5","key":"10.1016\/j.biopha.2025.118392_bib154","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1016\/j.clpt.2005.08.003","article-title":"The role of common variants of ABCB1, CYP3A4, and CYP3A5 genes in lipid-lowering efficacy and safety of simvastatin treatment","volume":"78","author":"Fiegenbaum","year":"2005","journal-title":"Clin. Pharmacol. Ther."},{"issue":"2","key":"10.1016\/j.biopha.2025.118392_bib155","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1038\/clpt.2009.79","article-title":"ABCG2 polymorphism markedly affects the pharmacokinetics of atorvastatin and rosuvastatin","volume":"86","author":"Keskitalo","year":"2009","journal-title":"Clin. Pharmacol. Ther."},{"issue":"3","key":"10.1016\/j.biopha.2025.118392_bib156","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0009763","article-title":"Genome-wide association of lipid-lowering response to statins in combined study populations","volume":"5","author":"Barber","year":"2010","journal-title":"PloS One"},{"issue":"4","key":"10.1016\/j.biopha.2025.118392_bib157","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1097\/HJR.0b013e328336a0dd","article-title":"KIF6 Trp719Arg polymorphism and the effect of statin therapy in elderly patients: results from the PROSPER study","volume":"17","author":"Iakoubova","year":"2010","journal-title":"Eur. J. Prev. Cardiol."},{"issue":"3","key":"10.1016\/j.biopha.2025.118392_bib158","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1002\/cpt.2674","article-title":"Genomewide association study of simvastatin pharmacokinetics","volume":"112","author":"Mykk\u00e4nen","year":"2022","journal-title":"Clin. Pharmacol. Ther."},{"issue":"7","key":"10.1016\/j.biopha.2025.118392_bib159","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0260824","article-title":"Association of cytochromes P450 3A4* 22 and 3A5* 3 genotypes and polymorphism with response to simvastatin in hypercholesterolemia patients","volume":"17","author":"Elalem","year":"2022","journal-title":"PloS One"},{"issue":"3","key":"10.1016\/j.biopha.2025.118392_bib160","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1016\/j.clinthera.2018.02.002","article-title":"Polymorphisms in CYP450 genes and the therapeutic effect of atorvastatin on ischemic stroke: a retrospective cohort study in Chinese population","volume":"40","author":"Peng","year":"2018","journal-title":"Clin. Ther."},{"issue":"6","key":"10.1016\/j.biopha.2025.118392_bib161","first-page":"352","article-title":"An association study of 43 SNPs in 16 candidate genes with atorvastatin response","volume":"5","author":"Thompson","year":"2005","journal-title":"Pharm. J."},{"issue":"8","key":"10.1016\/j.biopha.2025.118392_bib162","first-page":"CR512","article-title":"Lipid-lowering effect of fluvastatin in relation to cytochrome P450 2C9 variant alleles frequently distributed in the Czech population","volume":"18","author":"Buzkova","year":"2012","journal-title":"Med. Sci. Monit. Int. Med. J. Exp. Clin. Res."},{"issue":"5","key":"10.1016\/j.biopha.2025.118392_bib163","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1111\/jcpt.12176","article-title":"Gene polymorphism and frequencies of the NPC1L1 gene (rs2072183, rs217434 and rs217428) in Japanese patients with dyslipidemia","volume":"39","author":"Kashiwabara","year":"2014","journal-title":"J. Clin. Pharm. Ther."},{"issue":"5","key":"10.1016\/j.biopha.2025.118392_bib164","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1161\/HYPERTENSIONAHA.107.086926","article-title":"Peroxisome Proliferator-Activated receptor \u03b1\u2013Independent actions of fenofibrate exacerbates left ventricular dilation and fibrosis in chronic pressure overload","volume":"49","author":"Duhaney","year":"2007","journal-title":"Hypertension"},{"issue":"6","key":"10.1016\/j.biopha.2025.118392_bib165","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1161\/ATVBAHA.107.140103","article-title":"Fenofibrate effect on triglyceride and postprandial response of apolipoprotein A5 variants: the GOLDN study","volume":"27","author":"Lai","year":"2007","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"issue":"3","key":"10.1016\/j.biopha.2025.118392_bib166","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1097\/FPC.0b013e328333b99c","article-title":"PharmGKB very important pharmacogene: SLCO1B1","volume":"20","author":"Oshiro","year":"2010","journal-title":"Pharm. Genom."},{"issue":"5","key":"10.1016\/j.biopha.2025.118392_bib167","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1097\/FPC.0b013e328351a486","article-title":"Rare PPARA variants and extreme response to fenofibrate in the genetics of lipid-lowering drugs and diet network study","volume":"22","author":"Irvin","year":"2012","journal-title":"Pharm. Genom."},{"key":"10.1016\/j.biopha.2025.118392_bib168","article-title":"Increased plasma renin by vasodilators promotes the progression of abdominal aortic aneurysm","volume":"14","author":"Liu","year":"2023","journal-title":"Front. Pharmacol."},{"issue":"2","key":"10.1016\/j.biopha.2025.118392_bib169","doi-asserted-by":"crossref","first-page":"169","DOI":"10.2217\/pgs.13.202","article-title":"Different phenotypes of the NAT2 gene influences hydralazine antihypertensive response in patients with resistant hypertension","volume":"15","author":"Spinasse","year":"2014","journal-title":"Pharmacogenomics"},{"issue":"11","key":"10.1016\/j.biopha.2025.118392_bib170","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.2217\/14622416.9.11.1673","article-title":"Update on the pharmacogenetics of NATs: structural considerations","volume":"9","author":"Stanley","year":"2008","journal-title":"Pharmacogenomics"},{"key":"10.1016\/j.biopha.2025.118392_bib171","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/S0027-5107(02)00153-7","article-title":"Molecular genetics and function of NAT1 and NAT2: role in aromatic amine metabolism and carcinogenesis","volume":"506","author":"Hein","year":"2002","journal-title":"Mutat. Res. \/Fundam. Mol. Mech. Mutagen."},{"issue":"12","key":"10.1016\/j.biopha.2025.118392_bib172","doi-asserted-by":"crossref","first-page":"1678","DOI":"10.1002\/jcph.1477","article-title":"Effect of N-acetyltransferase 2 genotype on the pharmacokinetics of hydralazine during pregnancy","volume":"59","author":"Han","year":"2019","journal-title":"J. Clin. Pharmacol."},{"issue":"4","key":"10.1016\/j.biopha.2025.118392_bib173","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1111\/j.1365-2125.2010.03733.x","article-title":"Do selected drugs increase the risk of lupus? A matched case-control study","volume":"70","author":"Schoonen","year":"2010","journal-title":"Br. J. Clin. Pharmacol."},{"issue":"1-2","key":"10.1016\/j.biopha.2025.118392_bib174","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1080\/14622416.2025.2481025","article-title":"Pharmacogenomic markers associated with drug-induced QT prolongation: a systematic review","volume":"26","author":"Bentestuen","year":"2025","journal-title":"Pharmacogenomics"},{"issue":"3","key":"10.1016\/j.biopha.2025.118392_bib175","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1152\/physrev.00036.2011","article-title":"hERG K(+) channels: structure, function, and clinical significance","volume":"92","author":"Vandenberg","year":"2012","journal-title":"Physiol. Rev."},{"issue":"1879","key":"10.1016\/j.biopha.2025.118392_bib176","doi-asserted-by":"crossref","DOI":"10.1098\/rstb.2022.0164","article-title":"SCN5A channelopathy: arrhythmia, cardiomyopathy, epilepsy and beyond","volume":"378","author":"Remme","year":"2023","journal-title":"Philos. Trans. R. Soc. Lond. B Biol. Sci."},{"issue":"2","key":"10.1016\/j.biopha.2025.118392_bib177","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/j.pbiomolbio.2009.01.008","article-title":"Susceptibility genes & modifiers for cardiac arrhythmias","volume":"98","author":"Schulze-Bahr","year":"2008","journal-title":"Prog. Biophys. Mol. Biol."},{"issue":"1","key":"10.1016\/j.biopha.2025.118392_bib178","first-page":"55","article-title":"A NOS1AP gene variant is associated with a paradoxical increase of the QT-interval shortening effect of digoxin","volume":"22","author":"Soroush","year":"2022","journal-title":"Pharm. J."},{"issue":"3","key":"10.1016\/j.biopha.2025.118392_bib179","doi-asserted-by":"crossref","first-page":"160","DOI":"10.14744\/AnatolJCardiol.2022.2276","article-title":"Association between rs2200733 polymorphism of PITX2 gene and the risk of atrial fibrillation","volume":"27","author":"Shen Han","year":"2023","journal-title":"Anatol. J. Cardiol."},{"issue":"12","key":"10.1016\/j.biopha.2025.118392_bib180","doi-asserted-by":"crossref","DOI":"10.3390\/medicina59122057","article-title":"Associations between selected ADRB1 and CYP2D6 gene polymorphisms in children with ventricular and supraventricular arrhythmias","volume":"59","author":"Moric-Janiszewska","year":"2023","journal-title":"Medicina"},{"issue":"4","key":"10.1016\/j.biopha.2025.118392_bib181","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/j.ejmhg.2017.03.001","article-title":"CYP2D6 pharmacogenomics","volume":"18","author":"Gopisankar","year":"2017","journal-title":"Egypt. J. Med. Hum. Genet."},{"issue":"1","key":"10.1016\/j.biopha.2025.118392_bib182","doi-asserted-by":"crossref","first-page":"13","DOI":"10.14797\/mdcj-10-1-13","article-title":"Cardiovascular drugs and the genetic response","volume":"10","author":"Dandona","year":"2014","journal-title":"Methodist Debakey Cardiovasc J."},{"issue":"1","key":"10.1016\/j.biopha.2025.118392_bib183","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1161\/01.HYP.24.1.63","article-title":"Angiotensin II type 1 receptor gene polymorphisms in human essential hypertension","volume":"24","author":"Bonnardeaux","year":"1994","journal-title":"Hypertension"},{"key":"10.1016\/j.biopha.2025.118392_bib184","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1385\/MB:24:1:27","article-title":"Historical perspective of the renin-angiotensin system","volume":"24","author":"Hall","year":"2003","journal-title":"Mol. Biotechnol."},{"issue":"8","key":"10.1016\/j.biopha.2025.118392_bib185","article-title":"Angiotensin converting enzyme (ACE) inhibitors versus angiotensin receptor blockers for primary hypertension","author":"Li","year":"2014","journal-title":"Cochrane Database Syst. Rev."},{"issue":"1","key":"10.1016\/j.biopha.2025.118392_bib186","first-page":"14","article-title":"Renin\u2013angiotensin system gene polymorphisms: relationship with blood pressure and microalbuminuria in telmisartan-treated hypertensive patients","volume":"5","author":"Redon","year":"2005","journal-title":"Pharm. J."},{"issue":"15","key":"10.1016\/j.biopha.2025.118392_bib187","doi-asserted-by":"crossref","first-page":"1854","DOI":"10.1093\/eurheartj\/ehq169","article-title":"Genetic determinants of treatment benefit of the angiotensin-converting enzyme-inhibitor perindopril in patients with stable coronary artery disease","volume":"31","author":"Brugts","year":"2010","journal-title":"Eur. Heart J."},{"issue":"9","key":"10.1016\/j.biopha.2025.118392_bib188","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1038\/sj.ijo.0802064","article-title":"Body weight changes and the A-6G polymorphism of the angiotensinogen gene","volume":"26","author":"Chaves","year":"2002","journal-title":"Int. J. Obes."},{"issue":"4","key":"10.1016\/j.biopha.2025.118392_bib189","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1016\/S0895-7061(00)01284-X","article-title":"Angiotensin II AT1 receptor gene polymorphism and microalbuminuria in essential hypertension","volume":"14","author":"Chaves","year":"2001","journal-title":"Am. J. Hypertens."},{"issue":"9","key":"10.1016\/j.biopha.2025.118392_bib190","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1097\/FPC.0b013e328363c137","article-title":"Genetic variants associated with angiotensin-converting enzyme inhibitor-associated angioedema","volume":"23","author":"Pare","year":"2013","journal-title":"Pharm. Genom."},{"issue":"2","key":"10.1016\/j.biopha.2025.118392_bib191","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1007\/s40292-024-00634-4","article-title":"Systematic review article: new drug strategies for treating resistant Hypertension\u2014the importance of a mechanistic, personalized approach","volume":"31","author":"Nardoianni","year":"2024","journal-title":"High. Blood Press. Cardiovasc. Prev."},{"issue":"2","key":"10.1016\/j.biopha.2025.118392_bib192","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1007\/s40292-024-00634-4","article-title":"Systematic review article: new drug strategies for treating resistant hypertension-the importance of a mechanistic, personalized approach","volume":"31","author":"Nardoianni","year":"2024","journal-title":"High. Blood Press Cardiovasc Prev."},{"issue":"3","key":"10.1016\/j.biopha.2025.118392_bib193","article-title":"Sacubitril\/Valsartan vs ACE inhibitors or ARBs","volume":"4","author":"Evbayekha","year":"2025","journal-title":"A Syst. Rev. MetaAnal. Random Trials JACC Adv."},{"issue":"8","key":"10.1016\/j.biopha.2025.118392_bib194","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1093\/eurheartj\/ehaa1041","article-title":"Coronary artery compression by pectus excavatum and an epicardial pacing lead","volume":"42","author":"Spentzou","year":"2021","journal-title":"Eur. Heart J."},{"issue":"5","key":"10.1016\/j.biopha.2025.118392_bib195","doi-asserted-by":"crossref","first-page":"351","DOI":"10.7326\/M17-3203","article-title":"Prevention, detection, evaluation, and management of high blood pressure in adults: synopsis of the 2017 American college of Cardiology\/American heart association hypertension guideline","volume":"168","author":"Carey","year":"2018","journal-title":"Ann. Intern. Med."},{"issue":"1","key":"10.1016\/j.biopha.2025.118392_bib196","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1007\/s40362-016-0038-x","article-title":"Pharmacogenetics of thiazide diuretics: an update on Inter-individual variations","volume":"4","author":"Hammoud","year":"2016","journal-title":"Springe Sci. Rev."},{"issue":"1","key":"10.1016\/j.biopha.2025.118392_bib197","doi-asserted-by":"crossref","first-page":"195","DOI":"10.2478\/enr-2024-0023","article-title":"Alpha-adducin 1 (rs4961) gene and its expression associated with sodium sensitivity in hypertensive patients: a cohort study in the Western Ukrainian population","volume":"58","author":"Sydorchuk","year":"2024","journal-title":"Endocr. Regul."},{"issue":"3","key":"10.1016\/j.biopha.2025.118392_bib198","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1007\/s10741-018-09765-y","article-title":"Pharmacogenomics of amlodipine and hydrochlorothiazide therapy and the quest for improved control of hypertension: a mini review","volume":"24","author":"Johnson","year":"2019","journal-title":"Heart Fail Rev."},{"issue":"7","key":"10.1016\/j.biopha.2025.118392_bib199","doi-asserted-by":"crossref","DOI":"10.3390\/jpm14070664","article-title":"Genetic variation in ABCB1, ADRB1, CYP3A4, CYP3A5, NEDD4L and NR3C2 confers differential susceptibility to resistant hypertension among South Africans","volume":"14","author":"Katsukunya","year":"2024","journal-title":"J. Pers. Med."},{"key":"10.1016\/j.biopha.2025.118392_bib200","unstructured":"Pharmacogenomics in Prediction of Cardiovascular Drugs Adverse Reaction [Internet], 2022. Available from: \u3008https:\/\/clinicaltrials.gov\/study\/NCT05307718\u3009."},{"key":"10.1016\/j.biopha.2025.118392_bib201","unstructured":"The Texas Interprofessional Pharmacogenomics Registry and Repository [Internet], 2024. Available from: \u3008https:\/\/clinicaltrials.gov\/study\/NCT06726590\u3009."},{"key":"10.1016\/j.biopha.2025.118392_bib202","unstructured":"Physiopathological Study of Genetic Modulation of Cardiovascular Effect of PPAR-Alpha Activation (MAGNETIC-PPARA) [Internet], 2022. Available from: \u3008https:\/\/clinicaltrials.gov\/study\/NCT05542147\u3009."},{"key":"10.1016\/j.biopha.2025.118392_bib203","unstructured":"The 1200 Patients Project: Studying the Implementation of Clinical Pharmacogenomic Testing [Internet], 2011. Available from: \u3008https:\/\/clinicaltrials.gov\/study\/NCT01280825\u3009."},{"key":"10.1016\/j.biopha.2025.118392_bib204","unstructured":"Direct Oral Anticoagulant Levels in Chinese Patients With Atrial Fibrillation - A Real- World Pharmacokinetic Study [Internet], 2022. Available from: \u3008https:\/\/clinicaltrials.gov\/study\/NCT05378035\u3009."},{"key":"10.1016\/j.biopha.2025.118392_bib205","unstructured":"Pharmacogenomics of Warfarin in Hispanics and Latinos [Internet], 2016. Available from: \u3008https:\/\/clinicaltrials.gov\/study\/NCT02972385\u3009."},{"key":"10.1016\/j.biopha.2025.118392_bib206","unstructured":"Implementation of Onsite Rapid CYP2C19 Assay for Genotype Guided Dual Antiplatelet Therapy After Acute Ischemic Stroke [Internet], 2024. Available from: \u3008https:\/\/clinicaltrials.gov\/study\/NCT06292117\u3009."},{"key":"10.1016\/j.biopha.2025.118392_bib207","unstructured":"The Study of Monitoring and Dosing Guidance of Direct Oral Anticoagulants Based on Pharmacokinetics, Pharmacodynamics, and Pharmacogenomics [Internet], 2024. Available from: \u3008https:\/\/clinicaltrials.gov\/study\/NCT06362343\u3009."},{"issue":"6822","key":"10.1016\/j.biopha.2025.118392_bib208","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1038\/35057062","article-title":"Initial sequencing and analysis of the human genome","volume":"409","author":"Lander","year":"2001","journal-title":"Nature"},{"issue":"5","key":"10.1016\/j.biopha.2025.118392_bib209","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1111\/joim.13772","article-title":"Precision Medicine in cardiovascular therapeutics: evaluating the role of pharmacogenetic analysis prior to drug treatment","volume":"295","author":"Ingelman-Sundberg","year":"2024","journal-title":"J. Intern. Med."},{"issue":"10","key":"10.1016\/j.biopha.2025.118392_bib210","doi-asserted-by":"crossref","DOI":"10.1002\/hsr2.70139","article-title":"Pharmacogenomics revolutionizing cardiovascular therapeutics: a narrative review","volume":"7","author":"Inshutiyimana","year":"2024","journal-title":"Health Sci. Rep."},{"key":"10.1016\/j.biopha.2025.118392_bib211","doi-asserted-by":"crossref","DOI":"10.1017\/pcm.2023.17","article-title":"Cardiovascular precision Medicine - a pharmacogenomic perspective","volume":"1","author":"Padmanabhan","year":"2023","journal-title":"Camb. Prisms Precis. Med."},{"key":"10.1016\/j.biopha.2025.118392_bib212","doi-asserted-by":"crossref","DOI":"10.3389\/fcvm.2019.00091","article-title":"Relevance of Multi-Omics studies in cardiovascular diseases","volume":"6","author":"Leon-Mimila","year":"2019","journal-title":"Front. Cardiovasc. Med."},{"key":"10.1016\/j.biopha.2025.118392_bib213","doi-asserted-by":"crossref","DOI":"10.1093\/postmj\/qgaf069","article-title":"AI-enhanced telemedicine for personalized antiretroviral therapy in HIV patients with neurological comorbidities: a narrative review","author":"Mugisha","year":"2025","journal-title":"Postgrad. Med. J."},{"issue":"4","key":"10.1016\/j.biopha.2025.118392_bib214","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1161\/CIRCRESAHA.119.314629","article-title":"Precision versus traditional medicine-clinical questions trigger progress in basic science","volume":"124","author":"Schwartz","year":"2019","journal-title":"Circ. Res."},{"issue":"3","key":"10.1016\/j.biopha.2025.118392_bib215","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/j.mjafi.2021.06.021","article-title":"Precision medicine: concept and tools","volume":"77","author":"Naithani","year":"2021","journal-title":"Med. J. Armed Forces India"},{"issue":"7","key":"10.1016\/j.biopha.2025.118392_bib216","doi-asserted-by":"crossref","DOI":"10.3390\/biology12070997","article-title":"Next-Generation sequencing technology: current trends and advancements","volume":"12","author":"Satam","year":"2023","journal-title":"Biology"},{"issue":"11","key":"10.1016\/j.biopha.2025.118392_bib217","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1016\/j.humimm.2021.02.012","article-title":"Next-generation sequencing technologies: an overview","volume":"82","author":"Hu","year":"2021","journal-title":"Hum. Immunol."},{"issue":"11","key":"10.1016\/j.biopha.2025.118392_bib218","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a036798","article-title":"Next-Generation sequencing technologies","volume":"9","author":"McCombie","year":"2019","journal-title":"Cold Spring Harb. Perspect. Med."},{"key":"10.1016\/j.biopha.2025.118392_bib219","doi-asserted-by":"crossref","DOI":"10.1016\/j.cca.2023.117568","article-title":"Next-Generation sequencing transforming clinical practice and precision Medicine","volume":"551","author":"Yadav","year":"2023","journal-title":"Clin. Chim. Acta Int. J. Clin. Chem."},{"issue":"4","key":"10.1016\/j.biopha.2025.118392_bib220","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1111\/j.1467-7652.2009.00406.x","article-title":"Discovering genetic polymorphisms in next-generation sequencing data","volume":"7","author":"Imelfort","year":"2009","journal-title":"Plant Biotechnol. J."},{"issue":"10","key":"10.1016\/j.biopha.2025.118392_bib221","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1038\/s41431-022-01162-2","article-title":"Whole exome and genome sequencing in mendelian disorders: a diagnostic and health economic analysis","volume":"30","author":"Ewans","year":"2022","journal-title":"Eur. J. Hum. Genet."},{"issue":"1","key":"10.1016\/j.biopha.2025.118392_bib222","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2023.53514","article-title":"Cost-effectiveness of whole-genome vs whole-exome sequencing among children with suspected genetic disorders","volume":"7","author":"Nurchis","year":"2024","journal-title":"JAMA Netw. Open"},{"issue":"2","key":"10.1016\/j.biopha.2025.118392_bib223","doi-asserted-by":"crossref","DOI":"10.3390\/ijms25020804","article-title":"Diabetic vasculopathy: molecular mechanisms and clinical insights","volume":"25","author":"Jia","year":"2024","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.biopha.2025.118392_bib224","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2024.1326776","article-title":"From genes to drugs: CYP2C19 and pharmacogenetics in clinical practice","volume":"15","author":"Shubbar","year":"2024","journal-title":"Front. Pharmacol."},{"issue":"1","key":"10.1016\/j.biopha.2025.118392_bib225","doi-asserted-by":"crossref","DOI":"10.3390\/jpm8010001","article-title":"Pharmacogenomics of CYP2C9: functional and clinical considerations","volume":"8","author":"Daly","year":"2017","journal-title":"J. Pers. Med."},{"issue":"9","key":"10.1016\/j.biopha.2025.118392_bib226","doi-asserted-by":"crossref","first-page":"2759","DOI":"10.1038\/s41596-020-0353-1","article-title":"Tutorial: a guide to performing polygenic risk score analyses","volume":"15","author":"Choi","year":"2020","journal-title":"Nat. Protoc."},{"issue":"8","key":"10.1016\/j.biopha.2025.118392_bib227","doi-asserted-by":"crossref","DOI":"10.1111\/cts.13893","article-title":"Pharmacogenomics polygenic risk score: ready or not for prime time?","volume":"17","author":"Singh","year":"2024","journal-title":"Clin. Transl. Sci."},{"issue":"1","key":"10.1016\/j.biopha.2025.118392_bib228","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1186\/s13059-017-1215-1","article-title":"Multi-omics approaches to disease","volume":"18","author":"Hasin","year":"2017","journal-title":"Genome Biol."},{"issue":"1","key":"10.1016\/j.biopha.2025.118392_bib229","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1186\/s40246-020-00276-2","article-title":"Application of CRISPR\/Cas9 to human-induced pluripotent stem cells: from gene editing to drug discovery","volume":"14","author":"De Masi","year":"2020","journal-title":"Hum. Genom."},{"issue":"7668","key":"10.1016\/j.biopha.2025.118392_bib230","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1038\/nature23305","article-title":"Correction of a pathogenic gene mutation in human embryos","volume":"548","author":"Ma","year":"2017","journal-title":"Nature"},{"key":"10.1016\/j.biopha.2025.118392_bib231","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2022.106480","article-title":"CRISPR\/CAS9: a promising approach for the research and treatment of cardiovascular diseases","volume":"185","author":"Dong","year":"2022","journal-title":"Pharm. Res"},{"issue":"6","key":"10.1016\/j.biopha.2025.118392_bib232","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/j.tcm.2020.06.008","article-title":"Translating genomic insights into cardiovascular medicine: opportunities and challenges of CRISPR-Cas9","volume":"31","author":"Zhang","year":"2021","journal-title":"Trends Cardiovasc. Med."},{"issue":"3","key":"10.1016\/j.biopha.2025.118392_bib233","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.119.006513","article-title":"Continuous wearable monitoring analytics predict heart failure hospitalization: the LINK-HF multicenter study","volume":"13","author":"Stehlik","year":"2020","journal-title":"Circ. Heart Fail"},{"issue":"5","key":"10.1016\/j.biopha.2025.118392_bib234","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1001\/jamacardio.2018.0136","article-title":"Passive detection of atrial fibrillation using a commercially available smartwatch","volume":"3","author":"Tison","year":"2018","journal-title":"JAMA Cardiol."},{"issue":"01","key":"10.1016\/j.biopha.2025.118392_bib235","doi-asserted-by":"crossref","first-page":"96","DOI":"10.71292\/sdmi.v2i01.13","article-title":"Health monitoring through wearables: a systematic review of innovations in cardiovascular disease detection and prevention","volume":"2","author":"Sultana","year":"2025","journal-title":"Strateg. Data Manag. Innov."},{"issue":"7","key":"10.1016\/j.biopha.2025.118392_bib236","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.1016\/j.ajhg.2022.05.001","article-title":"Digital health-enabled genomics: opportunities and challenges","volume":"109","author":"Bombard","year":"2022","journal-title":"Am. J. Hum. Genet"},{"issue":"12","key":"10.1016\/j.biopha.2025.118392_bib237","doi-asserted-by":"crossref","DOI":"10.3390\/ijms22126319","article-title":"Expression quantitative trait loci (eQTLs) associated with retrotransposons demonstrate their modulatory effect on the transcriptome","volume":"22","author":"Koks","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.biopha.2025.118392_bib238","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1007\/978-1-61779-785-9_14","article-title":"eQTL","volume":"871","author":"Li","year":"2012","journal-title":"Methods Mol. Biol."},{"issue":"1","key":"10.1016\/j.biopha.2025.118392_bib239","doi-asserted-by":"crossref","first-page":"3030","DOI":"10.1038\/s41467-023-38795-w","article-title":"A computational method for cell type-specific expression quantitative trait loci mapping using bulk RNA-seq data","volume":"14","author":"Little","year":"2023","journal-title":"Nat. Commun."},{"issue":"1","key":"10.1016\/j.biopha.2025.118392_bib240","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1038\/s43586-021-00056-9","article-title":"Genome-wide association studies","volume":"1","author":"Uffelmann","year":"2021","journal-title":"Nat. Rev. Methods Prim."},{"key":"10.1016\/j.biopha.2025.118392_bib241","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.yjmcc.2021.01.011","article-title":"Clinical epigenomics for cardiovascular disease: diagnostics and therapies","volume":"154","author":"Fischer","year":"2021","journal-title":"J. Mol. Cell. Cardiol."},{"issue":"4","key":"10.1016\/j.biopha.2025.118392_bib242","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1177\/2040622314529325","article-title":"The emerging role of epigenetics in cardiovascular disease","volume":"5","author":"Abi Khalil","year":"2014","journal-title":"Ther. Adv. Chronic Dis."},{"issue":"2","key":"10.1016\/j.biopha.2025.118392_bib243","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.tcm.2006.11.004","article-title":"Proteomics and metabolomics combined in cardiovascular research","volume":"17","author":"Mayr","year":"2007","journal-title":"Trends Cardiovasc. Med."},{"issue":"8","key":"10.1016\/j.biopha.2025.118392_bib244","first-page":"657","article-title":"Proteomics and metabolomics for mechanistic insights and biomarker discovery in cardiovascular disease. Revista espanola de cardiologia (English ed)","volume":"66","author":"Barallobre-Barreiro","year":"2013"},{"issue":"9","key":"10.1016\/j.biopha.2025.118392_bib245","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1080\/14789450.2016.1217775","article-title":"Proteomics and metabolomics in biomarker discovery for cardiovascular diseases: progress and potential","volume":"13","author":"Tu\u00f1\u00f3n","year":"2016","journal-title":"Expert Rev. Proteom."},{"issue":"5","key":"10.1016\/j.biopha.2025.118392_bib246","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1038\/s41569-020-00477-1","article-title":"Systems biology in cardiovascular disease: a multiomics approach","volume":"18","author":"Joshi","year":"2021","journal-title":"Nat. Rev. Cardiol."},{"key":"10.1016\/j.biopha.2025.118392_bib247","doi-asserted-by":"crossref","first-page":"1683","DOI":"10.3389\/fimmu.2020.01683","article-title":"Systems biology approaches to understanding the human immune system","volume":"11","author":"Dhillon","year":"2020","journal-title":"Front. Immunol."},{"issue":"1","key":"10.1016\/j.biopha.2025.118392_bib248","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.mayocp.2013.10.021","article-title":"Preemptive genotyping for personalized Medicine: design of the right drug, right dose, right time-using genomic data to individualize treatment protocol","volume":"89","author":"Bielinski","year":"2014","journal-title":"Mayo Clin. Proc."},{"key":"10.1016\/j.biopha.2025.118392_bib249","series-title":"Disclosure: Aparna Thombare declares no relevant financial relationships with ineligible companies","article-title":"Point-of-Care testing. Statpearls. treasure island (FL) ineligible companies","author":"Larkins","year":"2025"},{"issue":"1","key":"10.1016\/j.biopha.2025.118392_bib250","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1515\/cclm-2024-0675","article-title":"Point-of-care testing: state-of-the art and perspectives","volume":"63","author":"Plebani","year":"2025","journal-title":"Clin. Chem. Lab. Med."},{"issue":"1","key":"10.1016\/j.biopha.2025.118392_bib251","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1002\/cpt.2387","article-title":"Pharmacogenomic clinical decision support: a review, How-to guide, and future vision","volume":"112","author":"Wake","year":"2022","journal-title":"Clin. Pharmacol. Ther."},{"issue":"7573","key":"10.1016\/j.biopha.2025.118392_bib252","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1038\/nature15817","article-title":"Pharmacogenomics in the clinic","volume":"526","author":"Relling","year":"2015","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.biopha.2025.118392_bib253","article-title":"The impact of child-specific characteristics on warfarin dosing requirements","volume":"8","author":"Alakeel","year":"2024","journal-title":"Res Pr. Thromb. Haemost."},{"issue":"3","key":"10.1016\/j.biopha.2025.118392_bib254","doi-asserted-by":"crossref","DOI":"10.3390\/genes15030379","article-title":"Pediatric beta blocker therapy: a comprehensive review of development and genetic variation to guide precision-based therapy in children, adolescents, and young adults","volume":"15","author":"Walton","year":"2024","journal-title":"Genes"},{"issue":"4","key":"10.1016\/j.biopha.2025.118392_bib255","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1038\/s41390-025-03819-2","article-title":"Genomics of pediatric cardiomyopathy","volume":"97","author":"Lee","year":"2025","journal-title":"Pediatr. Res."},{"issue":"3","key":"10.1016\/j.biopha.2025.118392_bib256","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1097\/FJC.0b013e3182163b82","article-title":"Pharmacogenomics of cardiovascular drugs and adverse effects in pediatrics","volume":"58","author":"Visscher","year":"2011","journal-title":"J. Cardiovasc Pharm."},{"issue":"5","key":"10.1016\/j.biopha.2025.118392_bib257","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1186\/gm344","article-title":"Pharmacogene regulatory elements: from discovery to applications","volume":"4","author":"Smith","year":"2012","journal-title":"Genome Med."},{"key":"10.1016\/j.biopha.2025.118392_bib258","doi-asserted-by":"crossref","DOI":"10.1017\/pcm.2023.17","article-title":"Cardiovascular precision Medicine \u2013 a pharmacogenomic perspective","volume":"1","author":"Padmanabhan","year":"2023","journal-title":"Camb. Prism. Precis. Med."},{"issue":"4","key":"10.1016\/j.biopha.2025.118392_bib259","first-page":"204","article-title":"Ethical, social and legal implications of pharmacogenomics: a critical review","volume":"4","author":"C.","year":"2002","journal-title":"Community Genet."},{"issue":"21","key":"10.1016\/j.biopha.2025.118392_bib260","doi-asserted-by":"crossref","first-page":"2049","DOI":"10.1001\/jama.2023.22345","article-title":"The genetic information privacy act: drawbacks and limitations","volume":"330","author":"Prince","year":"2023","journal-title":"Jama"},{"key":"10.1016\/j.biopha.2025.118392_bib261","first-page":"75","article-title":"Privacy of genetic information","volume":"52","author":"Setoyama","year":"2005","journal-title":"Osaka Univ. Law Rev."},{"key":"10.1016\/j.biopha.2025.118392_bib262","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1146\/annurev.genom.2.1.401","article-title":"Privacy and confidentiality of genetic information: what rules for the new science?","volume":"2","author":"Anderlik","year":"2001","journal-title":"Annu Rev. Genom. Hum. Genet"},{"issue":"3","key":"10.1016\/j.biopha.2025.118392_bib263","first-page":"476","article-title":"Discrimination as a consequence of genetic testing","volume":"50","author":"Billings","year":"1992","journal-title":"Am. J. Hum. Genet"},{"issue":"3","key":"10.1016\/j.biopha.2025.118392_bib264","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1038\/90032","article-title":"Consent and privacy in pharmacogenetic testing","volume":"28","author":"Robertson","year":"2001","journal-title":"Nat. Genet"},{"issue":"2","key":"10.1016\/j.biopha.2025.118392_bib265","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1007\/BF03351409","article-title":"The ethics of pharmacogenomics","volume":"23","author":"Neil","year":"2004","journal-title":"Monash Bioeth. Rev."},{"issue":"1","key":"10.1016\/j.biopha.2025.118392_bib266","doi-asserted-by":"crossref","DOI":"10.1093\/jlb\/lsz016","article-title":"Genetic discrimination: emerging ethical challenges in the context of advancing technology","volume":"7","author":"Chapman","year":"2020","journal-title":"J. Law Biosci."},{"key":"10.1016\/j.biopha.2025.118392_bib267","doi-asserted-by":"crossref","DOI":"10.3389\/fgene.2023.1099541","article-title":"Pharmacogenomics and health disparities, are we helping?","volume":"14","author":"Shaaban","year":"2023","journal-title":"Front Genet"},{"issue":"1","key":"10.1016\/j.biopha.2025.118392_bib268","first-page":"32","article-title":"Ethical concerns related to developing pharmacogenomic treatment strategies for addiction","volume":"6","author":"Shields","year":"2011","journal-title":"Addict. Sci. Clin. Pr."},{"issue":"1","key":"10.1016\/j.biopha.2025.118392_bib269","first-page":"13","article-title":"The role of pharmacogenetics and pharmacogenomics in improving translational medicine","volume":"6","author":"Dere","year":"2009","journal-title":"Clin. Cases Miner. Bone Metab. Off. J. Ital. Soc. Osteoporos. Miner. Metab. Skelet. Dis."},{"issue":"6","key":"10.1016\/j.biopha.2025.118392_bib270","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1007\/s11606-012-1988-6","article-title":"The genetic information nondiscrimination act (GINA): public policy and medical practice in the age of personalized Medicine","volume":"27","author":"Feldman","year":"2012","journal-title":"J. Gen. Intern Med."},{"issue":"8","key":"10.1016\/j.biopha.2025.118392_bib271","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1377\/hlthaff.2015.1476","article-title":"Using genetic technologies to reduce, rather than widen, health disparities","volume":"35","author":"Smith","year":"2016","journal-title":"Health Aff."},{"issue":"5","key":"10.1016\/j.biopha.2025.118392_bib272","doi-asserted-by":"crossref","first-page":"347","DOI":"10.2217\/pgs-2019-0175","article-title":"An assessment of patient perspectives on pharmacogenomics educational materials","volume":"21","author":"Asiedu","year":"2020","journal-title":"Pharmacogenomics"},{"key":"10.1016\/j.biopha.2025.118392_bib273","doi-asserted-by":"crossref","DOI":"10.1016\/j.pec.2023.107904","article-title":"Patient understanding of pharmacogenomic test results in clinical care","volume":"115","author":"Doyle","year":"2023","journal-title":"Patient Educ. Couns."},{"issue":"11","key":"10.1016\/j.biopha.2025.118392_bib274","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1016\/j.sapharm.2023.07.012","article-title":"Effectiveness of pharmacogenomics educational interventions on healthcare professionals and health professions students: a systematic review","volume":"19","author":"Omran","year":"2023","journal-title":"Res Soc. Adm. Pharm."},{"issue":"18","key":"10.1016\/j.biopha.2025.118392_bib275","doi-asserted-by":"crossref","first-page":"921","DOI":"10.2217\/pgs-2023-0191","article-title":"Pharmacogenomic knowledge and awareness among diverse patients treated with angiotensin converting enzyme inhibitors","volume":"24","author":"Naik","year":"2023","journal-title":"Pharmacogenomics"},{"issue":"3","key":"10.1016\/j.biopha.2025.118392_bib276","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1198\/sbr.2009.08076","article-title":"Sample size analysis for pharmacogenetic studies","volume":"2","author":"Tseng","year":"2010","journal-title":"Stat. Biopharm. Res."},{"issue":"1","key":"10.1016\/j.biopha.2025.118392_bib277","first-page":"7","article-title":"Integrating epigenomics into pharmacogenomic studies","volume":"2008","author":"Zhang","year":"2008","journal-title":"Pharmgenom. Pers. Med."},{"issue":"1","key":"10.1016\/j.biopha.2025.118392_bib278","doi-asserted-by":"crossref","first-page":"309","DOI":"10.3892\/etm.2015.2493","article-title":"Allele frequency distribution of CYP2C19*2 allelic variants associated with clopidogrel resistance in cardiac patients","volume":"10","author":"Rehman","year":"2015","journal-title":"Exp. Ther. Med"},{"issue":"1","key":"10.1016\/j.biopha.2025.118392_bib279","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1007\/s40119-024-00348-7","article-title":"Prevalence of CYP2C19*2 and CYP2C19*3 allelic variants and clopidogrel use in patients with cardiovascular disease in trinidad & tobago","volume":"13","author":"Jones","year":"2024","journal-title":"Cardiol. Ther."}],"container-title":["Biomedicine &amp; Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332225005864?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332225005864?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,8,21]],"date-time":"2025-08-21T01:15:27Z","timestamp":1755738927000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0753332225005864"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":279,"alternative-id":["S0753332225005864"],"URL":"https:\/\/doi.org\/10.1016\/j.biopha.2025.118392","relation":{},"ISSN":["0753-3322"],"issn-type":[{"value":"0753-3322","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pharmacogenomics in cardiac therapy: Personalizing treatment for heart health","name":"articletitle","label":"Article Title"},{"value":"Biomedicine & Pharmacotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biopha.2025.118392","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"118392"}}